Clinical Trial Update: Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

View source ↗

Summary

Registry study update assessing long-term safety of vamorolone (AGAMREE) in Duchenne muscular dystrophy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AGAMREE (Vamorolone)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Duchenne Muscular Dystrophy | Status: RECRUITING